Literature DB >> 15246977

Role of Cftr genotype in the response to chronic Pseudomonas aeruginosa lung infection in mice.

Anna M van Heeckeren1, Mark D Schluchter, Mitchell L Drumm, Pamela B Davis.   

Abstract

Patients with cystic fibrosis have a lesion in the cystic fibrosis transmembrane conductance regulator gene (CFTR), which is associated with abnormal regulation of other ion channels, abnormal glycosylation of secreted and cell surface molecules, and vulnerability to bacterial infection and inflammation in the lung usually leading to the death of these patients. The exact mechanism(s) by which mutation in CFTR leads to lung infection and inflammation is not clear. Mice bearing different mutations in the murine homolog to CFTR (Cftr) (R117H, S489X, Y122X, and DeltaF508, all backcrossed to the C57BL/6J background) were compared with respect to growth and in their ability to respond to lung infection elicited with Pseudomonas aeruginosa-laden agarose beads. Body weights of mice bearing mutations in Cftr were significantly smaller than wild-type mice at most ages. The inflammatory responses to P. aeruginosa-laden agarose beads were comparable in mice of all four Cftr mutant genotypes with respect to absolute and relative cell counts in bronchoalveolar lavage fluid, and cytokine levels (TNF-alpha, IL-1beta, IL-6, macrophage inflammatory protein-2, and keratinocyte chemoattractant) and eicosanoid levels (PGE2 and LTB4) in epithelial lining fluid: the few small differences observed occurred only between cystic fibrosis mice bearing the S489X mutation and those bearing the knockout mutation Y122X. Thus we cannot implicate either misprocessing of CFTR or failure of CFTR to reach the plasma membrane in the genesis of the excess inflammatory response of CF mice. Therefore, it appears that any functional defect in CFTR produces comparable inflammatory responses to lung infections with P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246977     DOI: 10.1152/ajplung.00387.2003

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  40 in total

1.  Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses.

Authors:  Christian Mueller; Sofia A Braag; Allison Keeler; Craig Hodges; Mitchell Drumm; Terence R Flotte
Journal:  Am J Respir Cell Mol Biol       Date:  2010-08-19       Impact factor: 6.914

2.  Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.

Authors:  Daniel Hsu; Patricia Taylor; Dave Fletcher; Rolf van Heeckeren; Jean Eastman; Anna van Heeckeren; Pamela Davis; James F Chmiel; Eric Pearlman; Tracey L Bonfield
Journal:  Infect Immun       Date:  2016-08-19       Impact factor: 3.441

Review 3.  Animal models for cystic fibrosis liver disease (CFLD).

Authors:  Romina Fiorotto; Mariangela Amenduni; Valeria Mariotti; Massimiliano Cadamuro; Luca Fabris; Carlo Spirli; Mario Strazzabosco
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-07-30       Impact factor: 5.187

4.  Monitoring infection and inflammation in murine models of cystic fibrosis with magnetic resonance imaging.

Authors:  Vipul R Sheth; R Christiaan van Heeckeren; Alma G Wilson; Anna M van Heeckeren; Mark D Pagel
Journal:  J Magn Reson Imaging       Date:  2008-08       Impact factor: 4.813

Review 5.  Barriers to inhaled gene therapy of obstructive lung diseases: A review.

Authors:  Namho Kim; Gregg A Duncan; Justin Hanes; Jung Soo Suk
Journal:  J Control Release       Date:  2016-05-16       Impact factor: 9.776

6.  Disease-causing mutations in the cystic fibrosis transmembrane conductance regulator determine the functional responses of alveolar macrophages.

Authors:  Ludmila V Deriy; Erwin A Gomez; Guangping Zhang; Daniel W Beacham; Jessika A Hopson; Alexander J Gallan; Pavel D Shevchenko; Vytautas P Bindokas; Deborah J Nelson
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

7.  Increased plasma membrane cholesterol in cystic fibrosis cells correlates with CFTR genotype and depends on de novo cholesterol synthesis.

Authors:  Danjun Fang; Richard H West; Mary E Manson; Jennifer Ruddy; Dechen Jiang; Stephen F Previs; Nitin D Sonawane; James D Burgess; Thomas J Kelley
Journal:  Respir Res       Date:  2010-05-20

8.  HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression.

Authors:  Douglas Conrad; Angela Wang; Raymond Pieters; Ferdinando Nicoletti; Katia Mangano; Anna M van Heeckeren; Steven K White; James M Frincke; Christopher L Reading; Dwight Stickney; Dominick L Auci
Journal:  J Inflamm (Lond)       Date:  2010-10-30       Impact factor: 4.981

9.  Leukotriene B4 mediates gammadelta T lymphocyte migration in response to diverse stimuli.

Authors:  Maria Fernanda de Souza Costa; Raquel de Souza-Martins; Mariana C de Souza; Cláudia F Benjamim; Bruno Piva; Bruno L Diaz; Marc Peters-Golden; Maria das Graças Henriques; Cláudio Canetti; Carmen Penido
Journal:  J Leukoc Biol       Date:  2009-10-30       Impact factor: 4.962

10.  The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

Authors:  David P Nichols; Assem G Ziady; Samuel L Shank; Jean F Eastman; Pamela B Davis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-21       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.